Article
From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
Tumori - 1 Jan 2000
Mazzoni Francesca, Rotella Virginia, Pratesi Nicola, Boni Luca, Simi Lisa, Orlando Claudio, Comin Camilla Eva, Maddau Cristina, Di Costanzo Francesco
Abstract excerpt
BACKGROUND: Inhibition of the epidermal growth factor receptor pathway with tyrosine kinase inhibitors can improve outcome of patients with advanced non-small cell lung cancer after first-line chemotherapy. The use of clinical characteristics and molecular markers may permit the identification of patients who are more likely to benefit from erlotinib. PATIENTS AND METHODS: Retrospective analysis of unselected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.